Article info
PDFIrritable bowel syndrome
An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome
- Correspondence to:
Dr A Wagner, Novartis Pharma AG, Lichstrasse 35, CH-4056, Basel, Switzerland;
amy.wagner{at}pharma.novartis.com
Citation
An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome
Publication history
- Accepted October 15, 2002
- First published May 1, 2003.
Online issue publication
October 26, 2017
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Copyright 2003 by Gut